Perrigo Company plc Increase (Decrease) in Prepaid Expense
Perrigo Company plc (PRGO) reported Increase (Decrease) in Prepaid Expense of -$25.90 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2023-02-28
- Perrigo Company plc increase (decrease) in prepaid expense for the quarter ending 2022-12-31 was -$19.20M.
- Perrigo Company plc increase (decrease) in prepaid expense for the quarter ending 2022-10-01 was $10.10M, a 180.56% increase year-over-year.
- Perrigo Company plc increase (decrease) in prepaid expense for the quarter ending 2022-07-02 was -$16.90M.
- Perrigo Company plc increase (decrease) in prepaid expense for the quarter ending 2022-04-02 was $100.00K, a 99.32% decline year-over-year.
- Perrigo Company plc increase (decrease) in prepaid expense for fiscal 2022 was -$25.90M.
- Perrigo Company plc increase (decrease) in prepaid expense for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Perrigo Company plc increase (decrease) in prepaid expense for fiscal 2020 was $12.30M.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$19.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$9.10M derived: sum of 2 quarters · filed 2023-02-28 | -$26.00M derived: sum of 3 quarters · filed 2023-02-28 | -$25.90M 10-K · filed 2023-02-28 |
| 2022-10-01 | $10.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$6.80M derived: sum of 2 quarters · filed 2022-11-08 | -$6.70M 10-Q · filed 2022-11-08 | -$8.50M derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-07-02 | -$16.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$16.80M 10-Q · filed 2022-08-09 | -$18.60M derived: sum of 3 quarters · filed 2023-02-28 | -$15.00M derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-04-02 | $100.00K 10-Q · filed 2022-05-11 | -$1.70M derived: sum of 2 quarters · filed 2023-02-28 | $1.90M derived: sum of 3 quarters · filed 2023-02-28 | -$14.60M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-12-31 | -$1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.80M derived: sum of 2 quarters · filed 2023-02-28 | -$14.70M derived: sum of 3 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 |
| 2021-10-02 | $3.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$12.90M derived: sum of 2 quarters · filed 2022-11-08 | $1.80M 10-Q · filed 2022-11-08 | -$9.70M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-07-03 | -$16.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$1.80M 10-Q · filed 2022-08-09 | -$13.30M derived: sum of 3 quarters · filed 2023-02-28 | -$21.90M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-04-03 | $14.70M 10-Q · filed 2022-05-11 | $3.20M derived: sum of 2 quarters · filed 2023-02-28 | -$5.40M derived: sum of 3 quarters · filed 2023-02-28 | -$6.40M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$11.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$20.10M derived: sum of 2 quarters · filed 2023-02-28 | -$21.10M derived: sum of 3 quarters · filed 2023-02-28 | $12.30M 10-K · filed 2023-02-28 |
| 2020-09-26 | -$8.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$9.60M derived: sum of 2 quarters · filed 2021-11-12 | $23.80M 10-Q · filed 2021-11-12 | |
| 2020-06-27 | -$1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $32.40M 10-Q · filed 2021-08-11 | ||
| 2020-03-28 | $33.40M 10-Q · filed 2021-05-12 | |||
| 2019-09-28 | $7.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.00M derived: sum of 2 quarters · filed 2020-11-05 | $4.70M 10-Q · filed 2020-11-05 | |
| 2019-06-29 | -$6.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$2.40M 10-Q · filed 2020-08-05 | ||
| 2019-03-30 | $3.70M 10-Q · filed 2020-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |